ABVX

Based on Abivax S.A.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Abivax do?

Abivax is a clinical-stage biopharmaceutical company based in Paris, France. It develops drug candidates for inflammatory diseases such as ulcerative colitis, Crohn's disease, and rheumatoid arthritis, as well as infectious diseases including HIV and dengue fever, and cancer. Its pipeline is built around two primary candidates, ABX464 and ABX196.

Does ABVX pay dividends?

Abivax does not currently pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available resources into its research and development pipeline. Investors should not expect income distributions in the near term.

When does ABVX report earnings?

Abivax reports financial results on a regular basis consistent with its listing obligations. Because it is a pre-revenue biotech, results primarily reflect R&D spending. For the latest reporting schedule, check Abivax's investor relations page directly.

Is ABVX a good stock to buy?

UQS Score rates ABVX as Poor overall, with Weak scores across Quality, Moat, and Growth pillars and an Elevated Valuation rating. This profile reflects the high-risk, pre-revenue nature of clinical-stage biotech investing. Pro members can view the full pillar breakdown to inform their own assessment.

Is ABVX overvalued?

The UQS Valuation pillar for ABVX is rated Elevated, suggesting the current market price may already incorporate optimistic expectations around clinical trial outcomes. For a pre-revenue company, valuation is particularly sensitive to pipeline progress.

How does ABVX compare to its competitors?

Abivax occupies a distinct niche focusing on small-molecule treatments for inflammatory and infectious diseases. Peers like Nuvalent and Krystal Biotech pursue oncology and gene therapy respectively, while ImmunityBio takes a broader immunotherapy approach. Each company carries a different risk and pipeline profile.

What is ABVX's market cap bracket?

Abivax is classified as a mid-cap company. This places it in a range where it has more resources than micro-cap biotechs but has not yet reached the scale of large established pharmaceutical companies.

Who founded Abivax?

Abivax was incorporated in 2013. Founding and leadership history is publicly documented and can be found on the company's official website and regulatory filings for the most accurate and current information.

Is ABVX a long-term buy?

From a long-term quality perspective, ABVX currently scores Poor on the UQS composite, with Weak ratings across Quality, Moat, and Growth. Long-term quality indicators remain underdeveloped until the company achieves commercial-stage milestones. The full analysis is available to Pro members.

What is the main competitive advantage of Abivax?

Abivax's Moat pillar is rated Weak, which is typical for clinical-stage biotechs without approved products. Its potential differentiation lies in its small-molecule approach to inflammatory disease and its licensing relationships with leading French research institutions, though these have yet to translate into a durable commercial moat.

What sector does ABVX belong to?

Abivax operates in the Healthcare sector, specifically within the clinical-stage biopharmaceutical segment. Companies in this segment are typically evaluated on pipeline progress and trial data rather than traditional financial performance metrics.

Is ABVX a growth stock or value stock?

Based on the UQS pillar profile, ABVX carries a Weak Growth rating and an Elevated Valuation rating. This combination means it does not currently fit cleanly into either category — it lacks demonstrated growth while trading at a premium, a profile common among speculative clinical-stage biotechs.

Abivax S.A. currently shows below-average quality metrics, suggesting challenges with profitability.

Abivax S.A. faces growth headwinds with declining or stagnant revenue trends.

Abivax S.A. maintains a reasonable risk profile with manageable debt levels.

Abivax S.A. appears expensively valued relative to its fundamentals and growth prospects.

Abivax S.A. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ABVX.

The UQS (Unified Quality Score) for Abivax S.A. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Abivax S.A.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Abivax S.A. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.